

DAFTAR PUSTAKA

1. (WHO) World Health Organization. Breast-Cancer @ Www.Who.Int [Internet]. 2020 [cited 2022 Mar 22]. Available from: <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>
2. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis* [Internet]. 2018;5(2):77- 106. Available from: <https://doi.org/10.1016/j.gendis.2018.05.001>
3. Merino MJ. Breast. Gattuso's Differ Diagnosis Surg Pathol [Internet]. 2021;419:721- 62. Available from: <https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf>
4. Release P. Latest world cancer statistics Global cancer burden rises to 14 . 1 million new cases in 2012 : Marked increase in breast cancers must be addressed. *Int Agency Res Cancer, World Heal Organ* [Internet]. 2013;(December):2012–4. Available from: http://www.iarc.fr/en/media-centre/pr/2013/pdfs/pr223_E.pdf
5. Panigroro S, Hernowo BS, Purwanto H. Panduan Penatalaksanaan Kanker Payudara (Breast Cancer Treatment Guideline). *J Kesehat Masy* [Internet]. 2019;4(4):1- 50. Available from: <http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf>
6. Widiana IK, Irawan H. Clinical and Subtypes of Breast Cancer in Indonesia. *Asian Pacific J Cancer Care*. 2020;5(4):281–5.
7. Eliyatkin N, Yalcin E, Zengel B, Aktaş S, Vardar E. Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. *J Breast Heal*. 2015;11(2):59–66.
8. Alluri P, Newman LA. Basal-like and triple-negative breast cancers. Searching for positives among many negatives. *Surg Oncol Clin N Am*. 2014;23(3):567–77.
9. Al-thoubaity FK. Molecular classification of breast cancer: A retrospective cohort study. *Ann Med Surg*. 2020;49(November 2019):44–8.
10. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. *Cancer Control*. 2010;17(3):173–6.
11. Caglevic C, Anabalón J, Soza C, Milla E, Gaete F, Carrasco AM, et al. Triple-negative breast cancer: The reality in Chile and in Latin America. *Ecancermedalscience*. 2019;13:1–8.

12. Al Farisyi M, Khambri D. Analisis Survival Pasien Kanker Payudara Usia Muda di RSUP DR. M. Djamil Padang Tahun 2008-2017. *J Kesehat Andalas*. 2018;7(Supplement 4):25.
13. Purwanto I, Heriyanto DS, Ghozali A, Widodo I, Dwiprahasto I, Aryandono T, et al. Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer. *World J Oncol*. 2020;11(5):216–22.
14. Agustina R, Windarti I, Ramadhian R., Rahmanisa S, Evi K. Hubungan Derajat Diferensiasi Histopatologik dengan Rekurensi Kanker Payudara di Rumah Sakit Umum Abdul Moeloek Bandar Lampung. *Fkui*. 2017;6(kanker payudara):4–8.
15. Primadanti SJ, Setiawan IGB. Prevalensi kanker payudara sub tipe triple negative pada wanita usia muda di Bali periode januari 2014 – oktober 2016. *E- Jurnal Med [Internet]*. 2018;7:87 - 90. Available from: <https://ojs.unud.ac.id/index.php/eum/article/view/37428/22738>
16. Jitariu AA, Cîmpean AM, Ribatti D, Raica M. Triple negative breast cancer: the kiss of death The Emerging Concept Of Triple Negative Breast Cancer. 2017;8(28):46652- 62. Available from: www.impactjournals.com/oncotarget
17. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Res*. 2020;22(1):1–13.
18. NCI Dictionary of Cancer Terms 1. Definition of Overall Survival Rate [Internet]. [cited 2022 Mar 23]. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/overall-survival-rate>
19. Institute NC. Definition Of Disease Free Survival [Internet]. [cited 2022 May 20]. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/disease-free-survival>
20. Maximiano S, Magalhães P, Guerreiro MP, Morgado M. Trastuzumab in the Treatment of Breast Cancer. *BioDrugs*. 2016;30(2):75–86.
21. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, et al. Basal-like and triple-negative breast cancers: A critical review with an emphasis on the implications for pathologists and oncologists. *Mod Pathol*. 2011;24(2):157–67.
22. Gao JJ, Swain SM. Luminal A Breast Cancer and Molecular Assays: A Review. *Oncologist*. 2018;23(5):556–65.
23. Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. *Breast Cancer Res*. 2011;13(6).

24. Li ZH, Hu PH, Tu JH, Yu NS. Luminal B breast cancer: Patterns of recurrence and clinical outcome. *Oncotarget*. 2016;7(40):65024–33.
25. The American Cancer Society. Treatment of Triple-negative Breast Cancer [Internet]. [cited 2022 Jun 8]. Available from: [https://www.cancer.org/cancer/breast-cancer/treatment/treatment-of-triple-negative.html#:~:text=Triple-negative breast cancer \(TNBC,the main systemic treatment option.](https://www.cancer.org/cancer/breast-cancer/treatment/treatment-of-triple-negative.html#:~:text=Triple-negative breast cancer (TNBC,the main systemic treatment option.)
26. Schnitt SJ. Classification and prognosis of invasive breast cancer: From morphology to molecular taxonomy. *Mod Pathol* [Internet]. 2010;23(S2):60-4. Available from: <http://dx.doi.org/10.1038/modpathol.2010.33>
27. von Minckwitz G, Martin M. Neoadjuvant treatments for triple-negative breast cancer (TNBC). *Ann Oncol* [Internet]. 2012;23(SUPPL. 6):vi35–9. Available from: <http://dx.doi.org/10.1093/annonc/mds193>
28. Lee JS, Yost SE, Yuan Y. Neoadjuvant treatment for triple negative breast cancer: Recent progresses and challenges. *Cancers (Basel)*. 2020;12(6).
29. Tian M, Zhong Y, Zhou F, Xie C, Zhou Y, Liao Z. Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis. *Oncol Lett*. 2015;9(6):2825–32.
30. Allyson B. Rivard; Laura Galarza-Paez; Diana C. Peterson. *Anatomy, Thorax, Breast* [Internet]. [cited 2022 May 27]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK519575/>
31. Yusuf S. Khan; Hussain Sajjad. *Anatomy, Thorax, Mammary Gland* [Internet]. [cited 2022 May 27]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK547666/>
32. Francesca Solari; Bracken Burns. *Anatomy, Thorax, Pectoralis Major Major* [Internet]. [cited 2022 May 27]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK525991/>
33. Zucca-Matthes G, Urban C, Vallejo A. Anatomy of the nipple and breast ducts. *Gland Surg*. 2016;5(1):32–6.
34. breast anatomy [Internet]. [cited 2022 May 29]. Available from: <https://visualsonline.cancer.gov/details.cfm?imageid=7127>
35. Stone K, Wheeler A. A Review of Anatomy, Physiology, and Benign Pathology of the Nipple. *Ann Surg Oncol*. 2015;22(10):3236–40.
36. National Cancer Institute. definition of cancer [Internet]. [cited 2022 May 29]. Available from: <https://www.cancer.gov/about cancer/understanding/what-is-cancer>

37. Definition of Breast Cancer [Internet]. [cited 2022 May 29]. Available from: https://www.cdc.gov/cancer/breast/basic_info/what-is-breast-cancer.htm
38. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk factors and preventions of breast cancer. *Int J Biol Sci*. 2017;13(11):1387–97.
39. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—An updated review. *Cancers (Basel)*. 2021;13(17):1–30.
40. Key T. Sex hormones and risk of breast cancer in premenopausal women: A collaborative reanalysis of individual participant data from seven prospective studies. *Lancet Oncol* [Internet]. 2013;14(10):1009–19. Available from: [http://dx.doi.org/10.1016/S1470-2045\(13\)70301-2](http://dx.doi.org/10.1016/S1470-2045(13)70301-2)
41. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin*. 2020;70(1):7–30.
42. Diering, Maxson & Mitchell, Freeman. 乳鼠心肌提取 HHS Public Access. *Physiol Behav*. 2018;176(1):139–48.
43. Angeli D, Salvi S, Tedaldi G. Genetic predisposition to breast and ovarian cancers: How many and which genes to test? *Int J Mol Sci*. 2020;21(3).
44. Fusco N, Sajjadi E, Venetis K, Gaudioso G, Lopez G, Corti C, et al. Pten alterations and their role in cancer management: Are we making headway on precision medicine? *Genes (Basel)*. 2020;11(7):1–19.
45. Albrektsen G, Heuch I, Hansen S, Kvåle G. Breast cancer risk by age at birth, time since birth and time intervals between births: Exploring interaction effects. *Br J Cancer*. 2005;92(1):167–75.
46. Ursin G, Bernstein L, Lord SJ, Karim R, Deapen D, Press MF, et al. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. *Br J Cancer*. 2005;93(3):364–71.
47. Checka CM, Chun JE, Schnabel FR, Lee J, Toth H. The relationship of mammographic density and age: Implications for breast cancer screening. *Am J Roentgenol*. 2012;198(3):292–5.
48. Kim EY, Chang Y, Ahn J, Yun JS, Park YL, Park CH, et al. Mammographic breast density, its changes, and breast cancer risk in premenopausal and postmenopausal women. *Cancer*. 2020;126(21):4687–96.
49. Duffy SW, Morrish OWE, Allgood PC, Black R, Gillan MGC, Willsher P, et al. Mammographic density and breast cancer risk in breast screening

assessment cases and women with a family history of breast cancer. *Eur J Cancer* [Internet]. 2018;88:48 - 56. Available from: <https://doi.org/10.1016/j.ejca.2017.10.022>

50. Tanggo V. Gradasi Histopatologi Sebagai Prediktor. 2017; Available from: <http://repository.unair.ac.id/56504/>
51. BELL ET. Diseases of the breast. Vol. 6, Bulletin. Minnesota Medical Foundation. 2014. 446 p.
52. Cong L, Liu Q, Zhang R, Cui M, Zhang X, Gao X, et al. Tumor size classification of the 8th edition of TNM staging system is superior to that of the 7th edition in predicting the survival outcome of pancreatic cancer patients after radical resection and adjuvant chemotherapy. *Sci Rep* [Internet]. 2018;8(1):1–9. Available from: <http://dx.doi.org/10.1038/s41598-018-28193-4>
53. Shah R, Rosso K, David Nathanson S. Pathogenesis, prevention, diagnosis and treatment of breast cancer. *World J Clin Oncol*. 2014;5(3):283–98.
54. Jessica A. Henderson; Doug Duffee; Troy Ferguson. Breast Examination Techniques [Internet]. StatPearls Publishing. 2022 [cited 2023 Feb 8]. Available from: <https://www.ncbi.nlm.nih.gov/NBK459179/>
55. Sultania M, Kataria K, Srivastava A, Misra MC, Parshad R, Dhar A, et al. Validation of Different Techniques in Physical Examination of Breast. *Indian J Surg*. 2017;79(3):219–25.
56. Helmi AF, Khambri D, Rustam R. The Relationship of Breast Cancer Subtypes with the Event of Metastasis in Dr. M. Djamil Hospital Padang. *Biosci Med J Biomed Transl Res*. 2021;5(4):1199–205.
57. ACS. Breast Cancer Early Detection and Diagnosis American Cancer Society Recommendations for the Early Detection of Breast Cancer. *Am Cancer Soc* [Internet]. 2016;1 - 55. Available from: <https://www.cancer.org/content/dam/CRC/PDF/Public/8579.00.pdf>
58. Wang L. Early diagnosis of breast cancer. *Sensors (Switzerland)*. 2017;17(7).
59. Subiyanto D, Kadi TA, Ismayiah I, Abdurrahman N, Utomo YP, Alifiansyah AR, et al. Subtipe Molekuler Kanker Payudara di RSUD Madiun dan Hubungannya dengan Grading Histopatologi. *Media Penelit dan Pengemb Kesehatan*. 2021;31(3):193–202.
60. Wiguna N, Manuaba I. Karakteristik pemeriksaan imunohistokimia pada pasien kanker payudara di rsup sanglah periode 2003-2012. Vol 3 No 7 (2014)*E-Jurnal Med Udayana* /. 2012;147:1–13.

61. Nascimento RG do, Otoni KM. Histological and molecular classification of breast cancer: what do we know? *Mastology*. 2020;30:1–8.
62. Dass SA, Tan KL, Rajan RS, Mokhtar NF, Adzmi ERM, Rahman WFWA, et al. Triple negative breast cancer: A review of present and future diagnostic modalities. *Med*. 2021;57(1):1–18.
63. Akshata Desai KA. Triple Negative Breast Cancer – An Overview. *Hered Genet*. 2012;2013(Suppl 2):1–7.
64. Suyatno, Pasaribu E. Kanker Payudara. In: *Bedah Onkologi Diagnosis dan Terapi*. 2nd ed. Suyatno, editor. Jakarta: CV. Sagung Seto; 2014. 253 p.
65. Azamris, Nurmasnyah, Dlidir D, Hariadi. Panduan Penatalaksanaan Kanker Payudara. In: *Panduan Penatalaksanaan Kanker Solid PERABOI 2010*. 1st ed. Wibawa Manuaba T, editor. Jakarta; 2010. 278 p.
66. Syahidah. *Kemoterapi Dan Efek Samping Kemoterapi*. *J Ners Indones* [Internet]. 2017; Available from: [repository.unimus.ac.id/876/3/BAB II.pdf](http://repository.unimus.ac.id/876/3/BAB%20II.pdf)
67. Price T. *Understanding Chemotherapy*. Nicole MacKee, editor. Sydney: Cancer Council Australia; 2022. 9 p.
68. Briani Sobri F, Azhar Y. Manajemen Operatif Kanker Payudara. In: Briani Sobri F, Azhar Y, Gunawan Wibiisana I, Rachman A, editors. *Manajemen Terkini Kanker Payudara*. 2nd ed. Jakarta: CV. Sagung Seto; 2018. p. 179.
69. Sardi NA. *Respon Kemoterapi Neoadjuvant pada Penderita Kanker Payudara*. Universitas Hasanudin; 2021.
70. Rustam R, Rachman A. Manajemen Terapi Kanker Payudara Triple Negative. In: Briani Sobri F, Azhar Y, Gunawan Wibiisana I, Rachman A, editors. *Manajemen Terkini Kanker Payudara*. 2nd ed. Jakarta: CV. Sagung Seto; 2018. p. 287–98.
71. Kementerian Kesehatan RI. *Pedoman Nasional Pelayanan Kedokteran Tatalaksana Kanker Payudara* [Internet]. 2018 [cited 2023 Nov 18]. p. 59. Available from: https://yankes.kemkes.go.id/unduh/fileunduh_1610414392_632733.pdf
72. Schwartz LH, Litière S, Vries E De, Ford R, Mandrekar S, Shankar L, et al. Committees. *Nucl Part Phys Proc*. 2017;289–290:vii.
73. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer* [Internet]. 2009;45(2):228–47. Available from: <http://dx.doi.org/10.1016/j.ejca.2008.10.026>

74. Wang L, Luo R, Lu Q, Jiang K, Hong R, Lee K. Miller – Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive , Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant Chemotherapy. 2021;11(September):1–10.
75. Hagens SC, de Groot S, Cohen D, Dekker TJA, Charehbili A, Meershoek-Klein Kranenbarg E, et al. Tumor-stroma ratio is associated with Miller-Payne score and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer. *Int J Cancer*. 2021;149(5):1181–8.
76. Zhu Q, Wang L, Tannenbaum S, Jr AR, Defusco P, Hegde P. Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria. 2014;1–14.
77. Zhao Y, Dong X, Li R, Ma X, Song J, Li Y, et al. Evaluation of the pathological response and prognosis following neoadjuvant chemotherapy in molecular subtypes of breast cancer. *Onco Targets Ther*. 2015;8:1511–21.
78. Mohapatra M, Sarma YS. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma. *J Cancer Res Ther*. 2020;16(6):1419–25.
79. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. *Breast*. 2003;12(5):320–7.
80. Dahlan MS. Besar Sampel dalam Penelitian Kedokteran dan Kesehatan. 4th ed. Kurniawan A, editor. *Epidemiologi Indonesia*; 2016. 13 p.
81. Naidoo K, Pinder SE. Chapter 3 Immunohistochemistry for Triple-Negative Breast Cancer. 2016;1406:39–51.
82. Hermansyah D, Rahayu Y, Azrah A, Pricilia G, Sufida S, Rifsal D, et al. Triple-Negative Breast Cancer Clinicopathology: A Single-Center Experience. *Indones J Cancer*. 2021;15(3):125.
83. Sporikova Z, Koudelakova V, Trojanec R, Hajduch M. Genetic Markers in Triple-Negative Breast Cancer. *Clin Breast Cancer* [Internet]. 2018;18(5):e841- 50. Available from: <http://dx.doi.org/10.1016/j.clbc.2018.07.023>
84. Anwar SL, Avanti WS, Nugroho AC, Choridah L, Dwianingsih EK, Harahap WA, et al. Risk factors of distant metastasis after surgery among different breast cancer subtypes: A hospital-based study in Indonesia. *World J Surg Oncol*. 2020;18(1):1–16.

85. Anna Bethania K, Rustamadji P. Hubungan Subtipe Molekular pada Karsinoma Payudara Invasif Hubungan Subtipe Molekular pada Karsinoma Payudara Invasif dengan Grade, Invasi Limfovaskular dan Metastasis KGB di Departemen Patologi Anatomik FKUI/RSCM Tahun 2019. *Maj Patol Indones*. 2022;31(1):392–9.
86. Derakhshan F, Reis-Filho JS. Pathogenesis of Triple-Negative Breast Cancer. *Bull N Y Acad Med* [Internet]. 2022;40(5):423–31. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9231507/pdf/nihms-1812222.pdf>
87. Fayaz MS, El-Sherify MS, El-Basmy A, Zlouf SA, Nazmy N, George T, et al. Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis. *Reports Pract Oncol Radiother* [Internet]. 2014;19(3):173- 81. Available from <http://dx.doi.org/10.1016/j.rpor.2013.08.007>
88. Jayadi T, Rustam BM, Kristi P, Dewi NC, Probowati W, Hariatmoko H, et al. The Association Between Age Groups with Clinicopathologic and Molecular Subtypes of Breast Cancer Patients. *Smart Med J*. 2022;5(2):93.
89. Gnanamuttupulle M, Henke O, Ntundu SH, Serventi F, Mwakipunda LE, Amsi P, et al. Clinicopathological characteristics of breast cancer patients from Northern Tanzania: Common aspects of late stage presentation and triple negative breast cancer. *Ecancermedicalsecience*. 2021;15:1–16.
90. Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. *Br J Cancer* [Internet]. 2012;106(6):1234–8. Available from: <http://dx.doi.org/10.1038/bjc.2012.31>
91. Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. *Ann Surg Oncol*. 2013;20(10):3254–8.
92. Fan L, Goss PE, Strasser-Weippl K. Current Status and Future Projections of Breast Cancer in Asia. *Breast Care*. 2015;10(6):372–8.
93. Balkenhol MCA, Vreuls W, Wauters CAP, Mol SJJ, van der Laak JAWM, Bult P. Histological subtypes in triple negative breast cancer are associated with specific information on survival. *Ann Diagn Pathol* [Internet]. 2020;46:151490. Available from: <https://doi.org/10.1016/j.anndiagpath.2020.151490>
94. Sugiarto Hadiyanto AV, Miranti IP, Prajoko YW, Istiadi H. Histological and Clinical Stage Profiles of Young-aged Breast Carcinoma. *Diponegoro Int Med J*. 2022;3(1):1–6.

95. Suhartati T. Kanker payudara pada wanita usia muda di bagian bedah onkologi rumah sakit umum pusat sanglah Denpasar tahun 2002 – 2012. 2013;(May):106.
96. Firasi AA, Jkd Y, Yudhanto E. Hubungan Usia Terhadap Derajat Diferensiasi Kanker Payudara Pada Wanita. J Kedokt Diponegoro [Internet]. 2016;5(4):327- 36. Available from: <https://ejournal3.undip.ac.id/index.php/medico/article/viewFile/14218/13750>
97. Kartini K, Lubis NL, Moriza T. Analisis Faktor Yang Mempengaruhi Keterlambatan Pengobatan Pada Wanita Penderita Kanker Payudara Di Rumah Sakit Umum Daerah Simeulue Tahun 2018. J Info Kesehat. 2019;17(1):16–34.
98. Fisusi FA, Akala EO. Drug Combinations in Breast Cancer Therapy. Pharm Nanotechnol. 2019;7(1):3–23.

